Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 41 of 3311 for:    schizophrenia

Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02874560
Recruitment Status : Completed
First Posted : August 22, 2016
Last Update Posted : October 22, 2018
Sponsor:
Information provided by (Responsible Party):
Janssen-Cilag Ltd.

Brief Summary:
In a population of patients suffering from schizophrenia being treated for an episode of clinical destabilization and followed for a period of twelve months, the main objective is to evaluate the proportion of patients achieving functional remission and its relationship to clinical remission.

Condition or disease
Schizophrenia

Detailed Description:
Prospective, national, noninterventional study. One year follow up with three evaluation dates (D0, D180 and D360). The participation of a subject in this study will in no way impact the regular care of the subject or any benefits they are otherwise entitled to. All treatment decisions will be made at the discretion of the participating physician, in accordance with his clinical practice and with approved local prescribing information. Only data available from clinical practice will be collected. Evaluation methods: patient history and clinical examination, clinical global impression (CGI): Improvement in CGI, social performance evaluation [functional remission of general schizophrenia (FROGS scale)], clinical remission evaluation: 8 items of the Positive and negative syndrome (PANSS) Scale, psychosocial remission evaluation (PSP scale), current insight evaluation: insight scale for psychosis, subjective well being under neuroleptic treatment (SWN scale), health condition [Euro quality of life - 5 Dimensions (EQ-5D)]; Judgment Criteria: functional remission is defined as an overall score of greater than or equal to (>=) 57 on the FROGS scale, functional response is defined as improvement of >= 7 points on the FROGS scale. Safety evaluation: no tolerance analysis will be performed, adverse event (AE) and serious adverse event (SAE) with J&J products will be collected and transmitted according to J&J timelines/process.

Layout table for study information
Study Type : Observational
Actual Enrollment : 364 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia
Actual Study Start Date : August 12, 2014
Actual Primary Completion Date : June 30, 2017
Actual Study Completion Date : July 12, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Group/Cohort
Schizophrenia
350 patients will be included in the study. The centers selection is planned with 100 hospital-based psychiatrists, in centers for preventive medicine (CMP) or in private settings. Each investigator should consecutively enroll patients fulfilling the selection criteria to participate in the study (mean expected number of participants per center is around 10).



Primary Outcome Measures :
  1. Clinical Remission [ Time Frame: 1 year Follow up ]
    Defined by the absence of a score greater than (>) 3 on the Positive and Negative Syndrome Scale (PANSS) 8 item scale at two consecutive evaluations (D0 and D180 or D180 and D360). The PANSS 8 items allows to evaluate the clinical remission, defined by a score less than or equal to (=<) 3 on each eight items during a six month minimum period. Each of the 8 PANSS items must be scored from 1 (not at all) to 7 (extremely). More the score is high, more the severity rate of the symptom is high.

  2. Functional Remission [ Time Frame: 1 year Follow up ]
    Defined by Functional Remission of General Schizophrenia (FROGS) scale global score and its relationship with clinical remission. FROGS scale: The "Functional Remission of General Schizophrenia" (FROGS) is a 19 items scale gathered in five fields ("Daily life", "Activities", "Adaptation Quality", "relational Life", "Health and treatment") used to evaluate the functional remission in schizophrenia. The 19 items must be scored from 1(not done) to 5 (perfectly done). The total score is 19 to 95. More the score is high, better the functioning abilities are is high.


Secondary Outcome Measures :
  1. Functional Response [ Time Frame: 1 year Follow up ]
    Defined as improvement from baseline of greater than or equal to (>=) 7 points on the FROGS scale. FROGS scale: The "Functional Remission of General Schizophrenia" (FROGS) is a 19 items scale gathered in five fields ("Daily life", "Activities", "Adaptation Quality", "relational Life", "Health and treatment") used to evaluate the functional remission in schizophrenia. The 19 items must be scored from 1(not done) to 5 (perfectly done). The total score is 19 to 95. More the score is high, better the functioning abilities are is high.

  2. Satisfactory Level of Functioning [ Time Frame: 1 year Follow up ]
    Defined by the absence of an item less than (<) 3 on the FROGS scale. FROGS scale: The "Functional Remission of General Schizophrenia" (FROGS) is a 19 items scale gathered in five fields ("Daily life", "Activities", "Adaptation Quality", "relational Life", "Health and treatment") used to evaluate the functional remission in schizophrenia. The 19 items must be scored from 1(not done) to 5 (perfectly done). The total score is 19 to 95. More the score is high, better the functioning abilities are is high.

  3. Predictive Clinical Characteristics [ Time Frame: 1 year Follow up ]
    Search for clinical variables predicting an improvement in social performance.

  4. Threshold Score [ Time Frame: 1 year Follow up ]
    Determine a threshold score to define functional remission, satisfactory functioning and optimal functioning on the Mini FROGS scale. Mini FROGS: 4 of the 19 items of FROGS, also scored from 1 (not done) to 5 (perfectly done), the total score is 4 to 20. More the score is high, better the functioning abilities are high.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 37 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients are followed in hospital, CMP or clinics for at least 6 months and are likely to be followed by the same team within the next year.
Criteria

Inclusion Criteria:

  • Patients must be male or female adult patients aged 18 to 37 years with a diagnosis of schizophrenia according to diagnostic and statistical manual of mental disorders (DSM-IV) criteria
  • Treated for schizophrenia
  • Having read understood and signed an informed consent (for patients under legal guardianship, the legal guardian will be informed by the physician)
  • Patients must have initiated a long-acting injectable antipsychotic treatment less than 2 months after a previous treatment
  • Patients must have been under monitoring by a treatment team from a hospital, a medical psychiatric centre or a clinic for at least 6 months and must be likely to be followed by the same team for the next year

Exclusion Criteria:

  • Resistant schizophrenia (no response after receiving two successive antipsychotic treatments at an effective dose, each over at least a four-week period)
  • Drug or alcohol dependence or abuse (other than nicotine or caffeine abuse) diagnosed according to DSM-IV in the month preceding the study inclusion process which according to the investigator could compromise the participation in the study
  • History of neuroleptic malignant syndrome
  • Inability to comply with the requirements of the study (e.g., intellectual deficiency, inability or unwillingness to answer questionnaires) according to the investigator's opinion
  • Patients under trusteeship or patient receiving psychiatric care without his consent (except patient under care program)
  • Participation in another study within 30 days prior to the study inclusion period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02874560


Locations
Layout table for location information
France
Paris, France
Sponsors and Collaborators
Janssen-Cilag Ltd.
Investigators
Layout table for investigator information
Study Director: Janssen-Cilag Ltd. Clinical Trial Janssen-Cilag Ltd.

Layout table for additonal information
Responsible Party: Janssen-Cilag Ltd.
ClinicalTrials.gov Identifier: NCT02874560     History of Changes
Other Study ID Numbers: CR103490
R092670SCH4033 ( Other Identifier: Janssen-Cilag Ltd. )
First Posted: August 22, 2016    Key Record Dates
Last Update Posted: October 22, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Janssen-Cilag Ltd.:
CNS
Antipsychotic
Functional remission
Observational study
FROGS
PSP
Functioning
Schizophrenia
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders